TG Therapeutics TGTX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's total equity?
- TG Therapeutics (TGTX) reported total equity of $583.13M in Q1 2026.
- How has TG Therapeutics's total equity changed year-over-year?
- TG Therapeutics's total equity increased by 145.7% year-over-year, from $237.29M to $583.13M.
- What is the long-term trend for TG Therapeutics's total equity?
- Over 5 years (2020 to 2025), TG Therapeutics's total equity has grown at a 4.5% compound annual growth rate (CAGR), from $519.35M to $648.02M.
- What does total equity mean?
- The net value of the company belonging to shareholders after all debts are paid.
- How do you interpret total equity?
- An increase indicates growth in book value through profits or capital raises, while a decrease suggests losses or capital depletion.
- How does total equity compare across companies?
- Used to calculate return on equity (ROE) and compare book value to market capitalization across the industry.